Latest Market Positioning News

GQG Partners reported a solid increase in Funds Under Management (FUM) to US$160.4 billion as of January 31, 2025, driven by strong net inflows of US$1.7 billion during the month.

Smartgroup has been appointed as the exclusive provider of salary packaging and novated leasing services for Monash Health’s 25,000 employees under a new multi-year contract starting April 2025.

Vection Technologies has elevated its market position by achieving Dell Technologies' highest partner tier, following a $4 million defence contract extension that underpins its growth in AI and XR solutions.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.

PM Capital Global Opportunities Fund Limited reported an 11% rise in half-year profit to $39.8 million and declared a higher fully franked interim dividend of 5.5 cents per share, reflecting strong portfolio performance amid global market volatility.

The Supreme Court of Western Australia has approved the merger between Horizon Minerals and Poseidon Nickel, setting the stage for a significant consolidation in the nickel sector. Key dates for trading suspension and scheme implementation have now been confirmed.

Hartshead Resources has submitted a development programme and budget to the P2607 Joint Venture, proposing a new gas export route through CalEnergy’s Saturn Banks pipeline, promising reduced capital expenditure and accelerated production timelines.

Adelong Gold Limited has raised $1.173 million through a placement to fund exploration and development at its NSW gold project and lithium ventures in Brazil. The capital raise, including free attaching options, signals investor confidence as the company advances towards production.

ikeGPS has halted acquisition talks after a private equity offer at a 62% premium failed to secure key shareholder backing, signaling confidence in its growth trajectory within the electric utility software market.

Hotel Property Investments (HPI) reported a solid $16.7 million statutory profit for H1 FY25, alongside a 3.2% rise in distributions and a successful debt refinancing that extends maturity and reduces costs.

Hotel Property Investments (HPI) reported a robust half-year profit of A$16.7 million, driven by rising rental income and property valuations, while managing significant takeover defence costs amid Charter Hall Retail REIT and Hostplus bids.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.